Eric Saunders, MD
Ophthalmology · Glen Rock, NJNPI 1699730937
Payments from drug & device makers
Across 115 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$376
- Bausch & Lomb Americas Inc.$341
- AbbVie$340
- Oyster Point Pharma, Inc.$318
- Alcon$129
- Tarsus Pharmaceuticals, Inc.$127
- plus $639 from 14 others
What the payments were for
- Food & beverage$2,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 22 | $376 |
| Bausch & Lomb Americas Inc. | 10 | $341 |
| AbbVie(2 entities) | 23 | $340 |
| Oyster Point Pharma, Inc. | 13 | $318 |
| Alcon | 7 | $129 |
| Tarsus Pharmaceuticals, Inc. | 7 | $127 |
| Glaukos Corporation | 1 | $93 |
| Aerie Pharmaceuticals, Inc. | 6 | $84 |
| Johnson & Johnson Vision Care, Inc. | 3 | $71 |
| Novartis | 5 | $68 |
| Astellas Pharma US Inc | 3 | $53 |
| Amgen | 3 | $51 |
| Biotissue Holdings Inc. | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $31 |
| Coopervision Inc. | 1 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| Balt USA, LLC | 1 | $24 |
| Ocular Therapeutix, Inc. | 1 | $14 |
| Sight Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,271 in reported general payments places this provider in the 60th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Travoprost | 12 | $1,618 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $231 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $220 |
| ErythromycinErythromycin Base | 17 | $206 |
| Latanoprost | 13 | $118 |
| Doxycycline Hyclate | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Glen Rock
- Adam FriendGlen Rock$12K
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.